Comparative Pharmacology
Head-to-head clinical analysis: BACLOFEN versus TRANCOPAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACLOFEN versus TRANCOPAL.
BACLOFEN vs TRANCOPAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
Trancopal (chlormezanone) is a centrally acting muscle relaxant and anxiolytic. Its exact mechanism is not fully understood, but it is believed to act on the central nervous system by depressing polysynaptic reflexes and possibly through GABAergic modulation.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
200-400 mg orally every 6 hours as needed for acute musculoskeletal pain; maximum 1.6 g per day.
None Documented
None Documented
Clinical Note
moderateBaclofen + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Baclofen is combined with Fluticasone propionate."
Clinical Note
moderateBaclofen + Clemastine
"The risk or severity of adverse effects can be increased when Baclofen is combined with Clemastine."
Clinical Note
moderateBaclofen + Venlafaxine
"The risk or severity of adverse effects can be increased when Baclofen is combined with Venlafaxine."
Clinical Note
moderateBaclofen + Nefazodone
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Terminal elimination half-life: 20-30 hours in healthy adults. Prolonged in hepatic impairment (up to 60 hours).
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
Primarily renal: ~95% as metabolites (glucuronides, sulfate conjugates) with <1% unchanged. Fecal: <5%.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The risk or severity of adverse effects can be increased when Baclofen is combined with Nefazodone."